Building atop its globally competitive command in monoclonal and bispecific antibody development, Akeso has executed a deliberate expansion into frontier therapeutic modalities by embedding AI end-to-end across the entire R&D and manufacturing continuum—from discovery and cell-line/process development through to smart manufacturing. The outcome is a tightly orchestrated portfolio of differentiated platforms: the Tetrabody antibody technology platform, the AI-powered drug R&D platform, the Dual-Shield ADC technology platform, the Dual-Lock T-cell engager (TCE) technology platform, the Tissue-Smart siRNA/mRNA technology platform, and the cell therapy technology platform. These assets collectively solidify Akeso’s global innovation edge, unlocking 0-to-N breakthroughs across multiple high-barrier domains where conventional therapeutic modalities have historically stalled.
Akeso is committed to developing first-in-class and best-in-class new drugs through efficient and groundbreaking R&D innovation. Since its establishment, the company has been committed to building fully integrated internal development capabilities. An end-to-end drug development platform, the Akeso Comprehensive Exploration Platform (ACE Platform), has been developed with great foresight, encompassing functionalities including drug target validation, antibody discovery and preclinical study, CMC manufacturing process development, and GMP-compliant commercialization production.
The ACE platform runs through the full life cycle of drug candidates through development to production and commercialization, reducing our reliance on the external service system. In addition, it ensures and promotes the efficient operation of the new drug development process, thereby increasing the possibility of a success rate and reducing the development cost. Based on this platform, we have developed over 50 innovative drug candidates with fully independent intellectual property rights, focusing on major diseases such as tumors and autoimmune, inflammatory, metabolic, and neurodegenerative diseases. Among them, 27 drug candidates have entered the clinical stage, with their production processes being developed by the internal platform.
Tetrabody technology is a proprietary technology independently developed by Akeso for the design and manufacture of innovative tetravalent bispecific antibodies. It overcomes CMC challenges such as low expression levels due to the high molecular weight of bispecific antibodies, process development obstacles due to the structural heterogeneity of bispecific antibodies, and non-druggability due to the lack of stability of bispecific antibodies.
Using our unique Tetrabody technology, we have successfully developed 15+ innovative, world-leading BsAbs, MsAbs, BsADCs, ADCs, and TCEs, including开坦尼® (PD-1/CTLA-4 bispecific antibody, Cadonilimab injection),依达方® (PD-1/VEGF bi-specific antibody,Ivonescimab injection) and AK130,etc. 开坦尼® is the world's first commercialized dual immune checkpoint inhibitor bispecific antibody to treat cancer. 依达方® is the world's first PD-1/VEGF bispecific antibody drug; and AK130 is the world's first and only TIGIT/TGF-β dual-targeting antibody fusion protein in research. This results fully demonstrate the strength of Akeso's innovative development strength and its leading position in the field of bispecific antibodies.
Akeso is vigorously promoting research on bispecific antibody-based combination therapies ，ushering in a new era of tumor immunotherapy (IO 2.0). Based on Cadonilimab and Ivonescimab, the exploration of combination therapies with many self-developed products or other drugs has shown promising synergies recently, and is expected to provide patients with superior therapeutic benefit. The social and industrial value of Akeso's innovative drugs will be fully presented in this development strategy.
Leveraging our leading edge in multi-specific antibodies, Akeso independently developed a proprietary Dual-Shield Antibody-Drug Conjugate (ADC) platform designed to overcome on-target off-tumor toxicity. Several pioneering third-generation ADCs and bispecific ADCs have advanced into clinical development.
Akeso has developed a proprietary, toxicity-reduced, efficacy-enhanced Dual-Lock T-cell engager (TCE) platform. Multiple pipeline programs are currently under development and advancing rapidly toward clinical trials.
Akeso has independently developed its proprietary Tissue-Smart siRNA platform with multiple extrahepatic delivery technologies, establishing a pipeline of innovative siRNA drug candidates across diverse therapeutic areas.
Keeping pace with the forefront of biotechnology, Akeso is pioneering a novel and universal CARL-NK cell therapy drug development platform, and enhancing the efficacy and safety of NK cell therapy.
Akeso is pioneering the global biopharmaceutical field with Flex-Nano mRNA Platform, a comprehensive technology spanning from mRNA sequence design to delivery systems. The company is advancing mRNA therapeutic cancer vaccines and gene therapy product pipelines, with candidate already in the clinical stage, securing a global first-mover advantage.
Akeso continues to iterate and scale its AI-powered, integrated drug discovery platform, which now provides comprehensive coverage across the entire R&D lifecycle for both antibody and nucleic acid therapeutics, while extending into additional frontier modalities. At its core lies a proprietary AI technology matrix that fuses high-precision structure prediction, immunogenicity prediction, fully automated humanization, and one-step sequence optimization. This closed-loop, data-rich architecture enables precise end-to-end engineering from sequence design to clinical development, significantly accelerating the efficient and high-throughput development of innovative therapies.
